why choose us

First received: June 20, 2023

Clinical Trial: Efficacy of Ra-223 in PSMA PET Optimally Selected Patients

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Castration-Resistant Prostate Carcinoma

Study Type: INTERVENTIONAL


Official Title: Efficacy of Ra-223 in PSMA PET Optimally Selected Patients

Brief Summary: This phase II trial studies how well prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scans (in combination with bone scans) work in selecting patients for Ra-223 radiation therapy that have castration-resistant prostate cancer that has spread from where it first started (primary site) to the bones (bone metastasis).Ra-223 is a type of therapy that emits radiation.Radiation gives off energy which can kill tumor cells and other cells that may support the tumor cells.Ra-223 is given by…

Read more